Research Article
[Retracted] Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C
Table 6
Distribution of AR among the three groups.
| | Symptoms | Control group (n = 26) | Tenofovir group (n = 26) | Entecavir group (n = 26) |
| | Joint muscle soreness | 0 | 1 | 0 | | Headache | 0 | 0 | 1 | | Fever | 0 | 1 | 1 | | Nausea | 2 | 1 | 1 | | Myocarditis | 2 | 1 | 1 | | Blood system diseases | 1 | 0 | 0 | | Proteinuria | 0 | 3 | 1 | | Number of adverse symptoms | 3 | 5 | 3 | | Types of adverse symptoms | 3 | 5 | 5 |
|
|
